Emergent BioSolutions Sees Q3 Sales $110.000M-$130.000M vs $209.000M Est
Benzinga Newsdesk 2 months ago
NewsGuidance
Emergent BioSolutions (NYSE:EBS) sees Q3 sales of $110.000 million-$130.000 million vs $209.000 million analyst estimate.
Emergent BioSolutions (NYSE:EBS) sees Q3 sales of $110.000 million-$130.000 million vs $209.000 million analyst estimate.